F/M Investments’s United Therapeutics UTHR Stock Holding History

F/M Investments’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.86M	Buy	8,975 +591	+7%	+$333K	0.25%	79
2026 Q1	$4.97M	Buy	8,384 +784	+10%	+$390K	0.33%	65
2025 Q4	$3.7M	Buy	7,600 +2,126	+39%	+$990K	0.14%	176
2025 Q3	$2.29M	Buy	5,474 +2,894	+112%	+$973K	0.09%	224
2025 Q2	$741K	Buy	2,580 +33	+1%	+$9.86K	0.03%	308
2025 Q1	$785K	Buy	2,547 +143	+6%	+$49K	0.03%	305
2024 Q4	$848K	Buy	+2,404	New	+$884K	0.03%	301

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

F/M Investments's UTHR Position: Q2 2026 in Review

F/M Investments increased its United Therapeutics (UTHR) stake by 7% in Q2 2026, buying an estimated $333K and bringing the position to 8,975 shares worth $4.86M. The position accounts for 0.25% of the portfolio, ranked #79.

F/M Investments first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.97M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

F/M Investments held 8,975 shares of United Therapeutics worth $4.86M as of Q2 2026.
F/M Investments bought 591 United Therapeutics shares in Q2 2026, an estimated $333K.
United Therapeutics made up 0.25% of F/M Investments's portfolio in Q2 2026, its #79 holding.
F/M Investments first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
F/M Investments's United Therapeutics position peaked at $4.97M in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.